It has been nearly two years since Pfizer’s sickle cell disease (SCD) therapy Oxbryta was approved in the UK, but patients will now be able to access the treatment after an agreement was reached ...

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.

As therapies for rare and neurological diseases earn accelerated approval, experts laud the program’s intent while remaining ...

In September 2024, Pfizer voluntarily withdrew large amounts of the sickle cell disease treatment medication Voxelotor, sold under the brand name Oxbryta, from worldwide markets. However ...

Sickle cell disease summit hosted by HHS highlights advancements and challenges. Learn about the summit and the experiences ...

Last month, Pfizer announced plans to yank its sickle cell drug Oxbryta from the market over ... and complexity of manufacturing.” “The disease is not going away, and we need something that ...

Oxbryta is manufactured as an oral therapy for patients with sickle cell disease. Hardiman began taking Oxbryta in 2020 under the belief that it would help manage his sickle cell disease.

Global Blood Therapeutics had developed Oxbryta that was used to treat haemolytic anaemia (excess breakdown of red blood cells) in patients aged 12 years and older who have sickle cell disease.

Sickle cell disease is a hereditary condition, which means a person inherits it from their biological parents. The condition occurs when a person inherits two copies of the hemoglobin beta (HBB ...

Newborn screening, comprehensive care, and disease-modifying therapies are changing the outlook for patients with sickle cell ...

Almost a year after two historic approvals, Pfizer is pulling a sickle cell disease treatment from the market, and the outlook for patients feels shakier.